- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00488007
Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids
Clinical Trial on Cognitive, Behavioural, Quality of Life and Medico-economic Benefits of Hearing Aids in Alzheimer Disease Patients Suffering From Presbycusis
This is a 12-months' randomized clinical trial that aims at studying the benefit of bilateral hearing aids in hearing impaired patients suffering from a slight to moderate stage Alzheimer disease.
The benefit of this intervention will be studied in the cognitive, behavioural, quality of life and economic fields.
2groups are involved in this trial: Intervention group: 12 months' treatment with active hearing aids, fitted hearing impairment Control group: 6 months' treatment with placebo hearing aids, followed with 6 months' active hearing aids, fitted hearing impairment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69495
- Xavier PERROT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- > 65 year-old
- Medical diagnosis of Alzheimer disease
- 15 ≤ MMSE ≤ 25
- No hearing aids in the last 2 years
- Motivated caregiver living with the patient
- Sensorineural hearing loss
Exclusion Criteria:
- Beginning of an anticholinesterasic treatment in the last 6 months
- Change in the anticholinesterasic treatment in the last 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active Hearing aids
Active
|
5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
|
|
Placebo Comparator: Inactive Hearing aids
Hearing aids turned off
|
5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive benefit evaluated thanks to the ADAS-Cog scale
Time Frame: Times of measurements: 0, 6th and 12th month
|
Times of measurements: 0, 6th and 12th month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive scales: MMSE, Grober and Buschke, Digit symbol test
Time Frame: 0, 6th and 12th month
|
0, 6th and 12th month
|
|
Behavioural scales: IADL, NPI
Time Frame: 1st week, 3rd 6th 9th and 12th month
|
1st week, 3rd 6th 9th and 12th month
|
|
Quality of life scales: Zarit scale and ADRQL
Time Frame: Zarit scale(every 2 months during the study time), ADRQL (0, 6th and 12th month)
|
Zarit scale(every 2 months during the study time), ADRQL (0, 6th and 12th month)
|
|
Consumption questionnaire
Time Frame: monthly
|
monthly
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc BONNEFOY, MD, Hospices Civils de Lyon
Publications and helpful links
General Publications
- Adrait A, Perrot X, Nguyen MF, Gueugnon M, Petitot C, Collet L, Roux A, Bonnefoy M; ADPHA study group. Do Hearing Aids Influence Behavioral and Psychological Symptoms of Dementia and Quality of Life in Hearing Impaired Alzheimer's Disease Patients and Their Caregivers? J Alzheimers Dis. 2017;58(1):109-121. doi: 10.3233/JAD-160792.
- Nguyen MF, Bonnefoy M, Adrait A, Gueugnon M, Petitot C, Collet L, Roux A, Perrot X; ADPHA study group. Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer's Disease and Hearing Loss: A Multicenter Controlled Randomized Trial. J Alzheimers Dis. 2017;58(1):123-137. doi: 10.3233/JAD-160793.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Otorhinolaryngologic Diseases
- Sensation Disorders
- Ear Diseases
- Hearing Loss
- Hearing Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Cognitive Dysfunction
- Alzheimer Disease
- Hearing Loss, Sensorineural
- Presbycusis
Other Study ID Numbers
- 2006.414
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.